News articles about Simulations Plus (NASDAQ:SLP) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Simulations Plus earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the technology company an impact score of 45.6902188277236 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Simulations Plus (NASDAQ SLP) opened at 14.95 on Wednesday. Simulations Plus has a 12 month low of $8.10 and a 12 month high of $16.15. The stock has a 50 day moving average price of $14.61 and a 200 day moving average price of $12.48. The stock has a market cap of $257.81 million, a P/E ratio of 47.46 and a beta of -0.71.
Simulations Plus (NASDAQ:SLP) last posted its earnings results on Friday, July 14th. The technology company reported $0.13 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.11 by $0.02. The firm had revenue of $6.75 million for the quarter, compared to the consensus estimate of $6.48 million. Simulations Plus had a net margin of 24.86% and a return on equity of 23.21%. Equities analysts anticipate that Simulations Plus will post $0.32 EPS for the current fiscal year.
Several brokerages have recently weighed in on SLP. Zacks Investment Research raised Simulations Plus from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a research report on Tuesday, July 25th. BidaskClub downgraded Simulations Plus from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st.
In other Simulations Plus news, CEO Walter S. Woltosz sold 18,500 shares of the stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $15.07, for a total transaction of $278,795.00. Following the transaction, the chief executive officer now directly owns 5,684,916 shares of the company’s stock, valued at $85,671,684.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 36.93% of the company’s stock.
Simulations Plus Company Profile
Simulations Plus, Inc (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour.
Receive News & Ratings for Simulations Plus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.